The DOI matches its Crossref record; 222 of the 222 references it cites were found in a registry or an index.
Non-coding RNAs and potential therapeutic targeting in cancer
Open accessAbstract
Recent advances have begun to clarify the physiological and pathological roles of non-coding RNAs (ncRNAs) in various diseases, including cancer. Among these, microRNAs (miRNAs) have been the most studied and have emerged as key players that are involved in the regulation of important growth regulatory pathways in cancer pathogenesis. The ability of a single ncRNA to modulate the expression of multiple downstream gene targets and associated pathways, have provided a rationale to pursue them for therapeutic drug development in cancer. In this context, early data from pre-clinical studies have demonstrated that synthetic miRNA-based therapeutic molecules, along with various protective coating approaches, has allowed for their efficient delivery and anti-tumor activity. In fact, some of the miRNA-based cancer therapeutic strategies have shown promising results even in early-phase human clinical trials. While the enthusiasm for ncRNA-based cancer therapeutics continue to evolve, the field is still in the midst of unraveling a more precise understanding of the molecular mechanisms and specific downstream therapeutic targets of other lesser studied ncRNAs such as the long-non-coding RNAs, transfer RNAs, circular RNAs, small nucleolar RNAs, and piwi-interacting RNAs. This review article provides the current state of knowledge and the evolving principles for ncRNA-based therapeutic approaches in cancer, and specifically highlights the importance of data to date and the approaches that are being developed to overcome the challenges associated with their delivery and mitigating the off-target effects in human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Items 201–222 of 222
Liu, Y., Qiu, M., Xu, Y., Wang, J., Zheng, Y., Li, M., Xu, L., & Yin, R. H. (2015) · Oncology Reports · doi:10.3892/or.2015.4364 · Cited by 58
Moro, M., Paolo, D. D., Milione, M., Centonze, G., Bornaghi, V., Borzi, C., Gandellini, P., Perri, P., Pastorino, U., Ponzoni, M., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.07.006 · Cited by 57
Márquez, J., Fernandez-Piñeiro, I., Araúzo-Bravo, M. J., Poschmann, G., Stühler, K., Khatib, A., Sánchez, A., Unda, F. J., Ibarretxe, G., Bernales, I., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31343 · Cited by 56
Identifying and targeting angiogenesis-related microRNAs in ovarian cancer
Chen, X., Mangala, L. S., Mooberry, L. K., Bayraktar, E., Dasari, S. K., Ma, S., Ivan, C., Court, K. A., Rodriguez‐Aguayo, C., Bayraktar, R., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0862-y · Cited by 56
Rui, M., Qu, Y., Gao, T., Ge, Y., Feng, C., & Xu, X. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s122171 · Cited by 55
Jin, H., Yu, Y., Chrisler, W., Xiong, Y., Hu, D., & Lei, C. (2011) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s8513 · Cited by 48
Highly efficient silencing of microRNA by heteroduplex oligonucleotides
Yoshioka, K., Kunieda, T., Asami, Y., Guo, H., Miyata, H., Yoshida‐Tanaka, K., Sujino, Y., Piao, W., Kuwahara, H., Nishina, K., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz492 · Cited by 44
Repression of Esophageal Neoplasia and Inflammatory Signaling by Anti-miR-31 Delivery In Vivo.
Taccioli, C., Garofalo, M., Chen, H.-P., Jiang, Y.-B., Tagliazucchi, G., di Leva, G., Alder, H., Fadda, P., Middleton, J. D., Smalley, K., et al. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv220 · Cited by 40
Lakings, D. B., Tp, W., Borek, E., Cw, G., Je, M., Longmore, J., & Rh, A. (1977) · PubMed · Cited by 38
Li, T., Zhang, Y., Meng, Y.-P., Bo, L.-S., & Ke, W. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2202-7 · Cited by 38
The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers
Mokhlis, H. A., Bayraktar, R., Kabil, N. N., Caner, A., Kahraman, N., Rodriguez‐Aguayo, C., Zambalde, É. P., Sheng, J., Karagoz, K., Kanlikilicer, P., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.019 · Cited by 38
Liu, W., Xu, Q., Sun, L. L., Dong, Q., He, C., & Yuan, Y. (2014) · Tumor Biology · doi:10.1007/s13277-014-2967-9 · Cited by 37
Inamoto, T., Taniguchi, K., Takahara, K., Iwatsuki, A., Takai, T., Komura, K., Yoshikawa, Y., Uchimoto, T., Saito, K., Tanda, N., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4129 · Cited by 30
Wang, Z., Zhao, K., Zhang, Y., Duan, X., & Zhao, Y. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2669-5 · Cited by 29
Prognostic value of long non-coding RNA MALAT1 in cancer patients
Wu, Y., Lu, W., Xu, J., Shi, Y., Zhang, H., & Xia, D. (2015) · Tumor Biology · doi:10.1007/s13277-015-3870-8 · Cited by 28
Wach, S., Brandl, M., Borchardt, H., Weigelt, K., Lukat, S., Nolte, E., Al-Janabi, O., Hart, M., Grässer, F. A., Giedl, J., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.020 · Cited by 26
Cancer Biomarkers and Big Data: A Planetary Science Approach
Crichton, D. J., Altınok, A., Amos, C. I., Anton, K., Cinquini, L., Colbert, M., Feng, Z., Goel, A., Kelly, S. C., Kincaid, H., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.006 · Cited by 23
Self-citationLane, J. S., Hoff, D. D. V., Cridebring, D., & Goel, A. (2020) · Cancers · doi:10.3390/cancers12061530 · Cited by 22
Self-citationKlimenko, O. V., & Штильман, М. И. (2013) · Cancer Gene Therapy · doi:10.1038/cgt.2013.11 · Cited by 20
Huang, X., Magnus, J., Kaimal, V., Karmali, P. P., Li, J., Walls, M., Prudente, R. Y., Sung, E., Sorourian, M., Lee, R., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0613 · Cited by 20
Design and development of antisense drugs
Malik, R., & Roy, I. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.10.1189 · Cited by 19
Matsuyama, T., Kandimalla, R., Ishikawa, T., Takahashi, N., Yamada, Y., Yasuno, M., Kinugasa, Y., Hansen, T. F., Fakih, M., Uetake, H., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33129 · Cited by 7
Self-citation
Cited by
RNA-based therapeutics: an overview and prospectus
Zhu, Y., Zhu, L., Wang, X., & Jin, H. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05075-2 · Cited by 623
Emerging epigenetic modifications in renal fibrosis: From mechanisms to treatments
Suo, X., Ge, Q., Peng, L., Zhu, Q., Zhang, M., Cheng, X., Wang, F., Jin, J., Wang, J., & Meng, X. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.09.012 · Cited by 8
Metadata
- Authors
- Toden, S., Zumwalt, T. J., & Goel, A.
- Venue
- Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 1875
- Issue
- 1
- Pages
- 188491
- ISSN
- 0304-419X (ISSN-L)
- OpenAlex
- W3112188147
- Cited by
- 327
- References
- 222
- FWCI
- 8.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.